Sandoz Perindopril Erbumine · DIN 02470225 · 2 mg · tablet
General benefitMarketed · checked November 19, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sandoz Perindopril Erbumine · DIN 02470225
Manufacturer: Sandoz Canada Inc.; listing date 2018-04-30
Health Canada: Marketed since 2018-03-05 · brand SANDOZ PERINDOPRIL ERBUMINE · ATC C09AA04 PERINDOPRIL · form Tablet · route Oral · ingredients PERINDOPRIL ERBUMINE 2 MG · company Sandoz canada incorporated · schedule Prescription
Sandoz Perindopril Erbumine: Formulary list price $0.16 per unit (the source does not state the unit; exact figure $0.1632). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02470225)
Source record
DIN 02470225: Sandoz Perindopril Erbumine
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800208; group id 343; item number 0778; lccId None; manufacturer id SDZ
Source form: Tab; strength: 2mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1632; ministry $0.1632
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02470225
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95921
Interchangeable products
AG-Perindopril · DIN 02481677 · $0.1632
Apo-Perindopril · DIN 02289261 · $0.1632
Auro-Perindopril · DIN 02459817 · $0.1632
Bio-Perindopril · DIN 02501309 · $0.1632
Coversyl · DIN 02123274 · $0.1632
Jamp Perindopril Erbumine · DIN 02527200 · $0.1632
Jamp-Perindopril · DIN 02477009 · $0.1632
M-Perindopril Erbumine · DIN 02482924 · $0.1632
Mar-Perindopril · DIN 02474824 · $0.1632
Mint-Perindopril · DIN 02476762 · $0.1632
NRA-Perindopril · DIN 02489015 · $0.1632
PMS-Perindopril · DIN 02470675 · $0.1632
Perindopril Erbumine · DIN 02479877 · $0.1632
Perindopril Erbumine · DIN 02481634 · $0.1632
Teva-Perindopril · DIN 02464985 · $0.1632
Shortage status: not checked (no credentials)